India approves new nasal vaccine against COVID-19
News » Health
Indian medical company Bharat Biotech has created a new alternative to conventional injection vaccines.
Bharat Biotech has recently developed a new COVID-19 vaccine, iNCOVACC, that can be enter nasally. This is reported by the Jerusalem Post.
This new vaccine stimulates an immune response based on tissues lining the nasal cavity.
The Central Drug Standards Authority of India approved the vaccine for general use in December 2022 with the possibility of a booster vaccination. The nasal vaccine is expected to cost Rs 800 (US$10) per dose in private hospitals and Rs 325 per dose in public hospitals.
Scientists believe nasal vaccines can provide additional immunity in the nasal mucosa and upper respiratory tract. It is known that COVID enters the body through these channels.
Follow us on Telegram
Related Posts
About The Author
Elizabeth
Elizabeth Stone has been a reporter on the news desk since 2013. Before that she wrote about young adolescence and family dynamics for Styles and was the legal affairs correspondent for the Metro desk. Before joining The Quebec Telegram, Elizabeth Stone worked as a staff writer at the Village Voice and a freelancer for Newsday, The Wall Street Journal, GQ and Mirabella. To get in touch, contact me through my stone@qtelegram.com 1-800-268-7116